Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 1204 - файл
.pdf
151
https://t.me/med1917
82. Diagnostic Principles for Chronic Gastritis Associated with Duodenogastric Reflux
/ M. A. Livzan [et al.] // Diagnostics. — 2023. — Vol. 13, iss. 2. — P. 186. DOI:
10.3390/diagnostics13020186.
83. Dietary restrictions during ambulatory monitoring of duodenogastroesophageal
reflux / J. Tack, R. Bisschops, G. Koek, [et al.] // Digestive Diseases and Sciences. –
2003. – Vol. 48. – № 7. – P. 1213–1220. DOI: 10.1023/a:1024130419914.
84. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged
esophageal epithelium / N.A. Tobey, S.S. Hosseini, C.M. Argote, [et al.] // American
Journal of Gastroenterology. – 2004. – Vol. 99(1). – P. 13-22. DOI: 10.1046/j.1572-
0241.2003.04018.x.
85. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts
reflux burden and symptomatic outcome in gastro-oesophageal reflux disease / A. Patel,
D. Wang, N. Sainani, [et al.] // Alimentary Pharmacology & Therapeutics. – 2016. – Vol.
44(8). – P. 890-8. DOI: 10.1111/apt.13777.
86. Does the addition of a prokinetic to proton pump inhibitor therapy help reduce
duodenogastro-oesophageal reflux in patients with Barrett’s oesophagus? / A. Smythe,
N.C. Bird, G.P. Troy, [et al.] // European Journal of Gastroenterology & Hepatology. –
2003. – Vol. 15. – № 3. – P. 305–312. doi: 10.1097/00042737-200303000-00014.
87. Dose-dependent effects of lesogaberan on reflux measures in patients with
refractory gastroesophageal reflux disease: a randomized, placebo-controlled study / PB
Jr. Miner, DG. Silberg, M. Ruth, [et al.] // BMC Gastroenterol. – 2014. – No. 188. DOI:
10.1186/1471-230X-14-188.
88. Effect of cisapride on oesophageal motility and duodeno-gastro–oesophageal
reflux in patients with Barrett’s oesophagus / A. Smythe, N. Bird, G. Troy, [et al.] //
European Journal of Gastroenterology & Hepatology. – 1997. – Vol. 9. – P. 1–5.
89. Effect of the GABAB agonist baclofen in patients with symptoms and duodenogastro-oesophageal reflux refractory to proton pump inhibitors / G.H. Koek, D. Sifrim,
T. Lerut, [et al.] // Gut. – 2003. – Vol. 52. – P. 1397–1402.
90. Effects of lesogaberan on reflux and lower esophageal sphincter function in
patients with gastroesophageal reflux disease / GE. Boeckxstaens, H. Beaumont, V.
152
https://t.me/med1917
Mertens, [et al.] // Gastroenterology. – 2010. – Vol. 139. – No. 2. – P. 409–17. DOI:
10.1053/j.gastro.2010.04.051.
91. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a
randomised controlled trial / N.J. Shaheen, H. Denison, K. Björck, [et al.] // Gut. – 2013.
– Vol. 62. – No. 9. – P. 1248–55. DOI: 10.1136/gutjnl-2012-302737.
92. Endoscopic Ex Vivo Evaluation of Bile Concentrations by Narrow Band Imaging:
A Pilot Study / R. Maselli, H. Inoue, H. Ikeda, [et al.] // Gastroenterology Research and
Practice. – 2015. – Vol. 2015. – P. 367848. DOI: 10.1155/2015/367848.
93. Esophageal development and epithelial homeostasis / S.L. Rosekrans, B. Baan, V.
Muncan, [et al.] // American Journal of Physiology-Gastrointestinal and Liver
Physiology. – 2015. – Vol. 309(4). – P. G216-28. DOI: 10.1152/ajpgi.00088.2015.
94. Esophageal intraluminal baseline impedance is associated with severity of acid
reflux and epithelial structural abnormalities in patients with gastroesophageal reflux
disease / C. Zhong, L. Duan, K. Wang, [et al.] // Journal of Gastroenterology. – 2013. –
Vol. 48(5). – P. 601-10. DOI: 10.1007/s00535-012-0689-6.
95. Esophageal Mucosal Resistance in Reflux Esophagitis: What We Have Learned So
Far and What Remains to Be Learned / I.V. Maev, M.A. Livzan, S.I. Mozgovoi, [et al.]
// Diagnostics (Basel). – 2023. – Vol. 13(16). – P. 2664. DOI:
10.3390/diagnostics13162664.
96. Expression and significance of CDX2, FXR, and TGR5 in esophageal cancer / H
Zhang, X Qu, N Wang, [et al.] // International Journal of Clinical and Experimental
Pathology. – 2022. – Vol. 15. – № 9. – P. 354-363.
97. Expression of bile acid transporting proteins in Barrett’s esophagus and esophageal
adenocarcinoma / K. Dvorak, G.S. Watts, L. Ramsey, [et al.] // American Journal of
Gastroenterology. – 2009. – Vol. 104. – № 2. – P. 302-9. DOI: 10.1038/ajg.2008.85.
98. Expression of VEGF, EGF, and Their Receptors in Squamous Esophageal Mucosa,
with Correlations to Histological Findings and Endoscopic Minimal Changes, in Patients
with Different GERD Phenotypes / J. Wasielica-Berger, P. Rogalski, A. ŚwidnickaSiergiejko, [et al.] // International Journal of Environmental Research and Public Health.
– 2022. – Vol. 19. – № 9. – P. 5298. DOI: 10.3390/IJERPH19095298.
153
https://t.me/med1917
99. Fang, Y. P63 Deficiency and CDX2 Overexpression Lead to Barrett’s-Like
Metaplasia in Mouse Esophageal Epithelium / Y. Fang, W. Li, X. Chen // Digestive
Diseases and Sciences. – 2021. – Vol. 66. – № 12. – P. 4263-4273. doi: 10.1007/s10620020-06756-8.
100. Fang, Y. P63 Deficiency and CDX2 Overexpression Lead to Barrett’s-Like
Metaplasia in Mouse Esophageal Epithelium / Y. Fang, W. Li, X. Chen // Digestive
Diseases and Sciences. – 2021. – Vol. 66. – № 12. – P. 4263-4273. DOI: 10.1007/s10620-
020-06756-8.
101. Gastroesophageal Mucosal Injury after Cholecystectomy: An Indication for
Surveillance? / S. N. Gilani [et al.] // Journal of the American College of Surgeons. —
2017. — Vol. 224, iss. 3. — P. 319-326. DOI:10.1016/j.jamcollsurg.2016.12.003.
102. Gastroesophageal reflux disease poorly responsive to single-dose proton pump
inhibitors in patients without Barrett’s esophagus: acid reflux, bile reflux, or both? / J.
Tack, G. Koek, I. Demedts, [et al.] // American Journal of Gastroenterology. – 2004. –
Vol. 99. – № 6. – P. 981–988. DOI: 10.1111/j.1572-0241.2004.04171.x.
103. Green, D.R. Cell death and the immune system: getting to how and why / D.R.
Green // Immunological Reviews. – 2017. – Vol. 277. – P. 4-8.
104. Growth factors expression in patients with erosive esophagitis / J.C. Luo, H.Y. Lin,
C.L. Lu, [et al.] // Translational Research. – 2008. – Vol. 152. – № 2. – P. 81-7. DOI:
10.1016/J.TRSL.2008.05.010.
105. Hashimoto, N. Cholecystectomy and Duodenogastric Reflux: Reflux of Duodenal
Content Induces Esophageal Carcinogenesis / N. Hashimoto // Clinical Surgery. – 2018.
– Vol. 3. – P. 1867.
106. Hofmann, A. F. Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology,
and Therapeutics / A. F. Hofmann, L. R. Hagey // Cellular and Molecular Life Sciences.
– 2008. – Vol. 65. – P. 2461 – 2483.
107. Hyvärinen, H. Relationship of previous cholecystectomy to oesophagitis and
gastroduodenal ulcers / H. Hyvärinen // Hepatogastroenterology. – 1987. – Vol. 34. – №
2. – P. 74-80.
154
https://t.me/med1917
108. Immunohistochemical overexpression of the p53 protein and Ki-67 (MIB-1)
antigen in patients with GERD and chronic esophagitis / M. Binato, R. Fagundes, R.
Gurski, [et al.] // Applied Immunohistochemistry & Molecular Morphology. – 2010. –
Vol. 18. – № 3. – P. 236-43. DOI: 10.1097/PAI.0b013e3181c49134.
109. Impact of pantoprazole on duodeno-gastro-esophageal reflux (DGER) / S. Kunsch,
A. Neesse, T. Linhart, [et al.] // Zeitschrift für Gastroenterologie. – 2009. – Vol. 47. – №
3. – P. 277–282. DOI: 10.1055/s-2008-1027865.
110. Impairment of chemical clearance and mucosal integrity distinguishes
hypersensitive esophagus from functional heartburn / M. Frazzoni, N. de Bortoli, L.
Frazzoni, [et al.] // Journal of Gastroenterology. – 2017. – Vol. 52(4). – P. 444-451. DOI:
10.1007/s00535-016-1226-9.
111. Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives /
M. Frazzoni, N. de Bortoli, L. Frazzoni, [et al.] // Digestive Diseases and Sciences. –
2017. – Vol. 62. – № 8. – P. 1881–1889. DOI: 10.1007/s10620-017-4625-8.
112. In Barrett’s esophagus patients and Barrett’s cell lines, ursodeoxycholic acid
increases antioxidant expression and prevents DNA damage by bile acids / S. Peng, X.
Huo, D. Rezaei, [et al.] // American Journal of Physiology-Gastrointestinal and Liver
Physiology. – 2014. – Vol. 307. – P. 129–139.
113. Increased Duodeno-Gastro-Esophageal Reflux (DGER) in symptomatic GERD
patients with a history of cholecystectomy / S. Kunsch, A. Neesse, J. Huth, [et al.] //
Zeitschrift für Gastroenterologie. – 2009. – Vol. 47. – № 8. – P. 744-748. DOI: 10.1055/s0028-1109176.
114. Increased expression of VEGF, COX-2, and Ki-67 in Barrett’s esophagus: does the
length matter? / E. Zampeli, G. Karamanolis, G. Morfopoulos, [et al.] // Digestive
Diseases and Sciences. – 2012. – Vol. 57. – № 5. – P. 1190-6. DOI: 10.1007/S10620011-1990-6.
115. Influence of pantoprazole on oesophageal motility, and bile and acid reflux in
patients with oesophagitis / P. Netzer, A. Gut, R. Brundler, [et al.] // Alimentary
Pharmacology & Therapeutics. – 2001. – Vol. 15. – № 9. – P. 1375–1384. DOI:
10.1046/j.1365-2036.2001.01069.x.
155
https://t.me/med1917
116. Ivy, A. C. A hormone mechanism for gall-bladder contraction and evacuation / A.
C. Ivy, E. Oldberg // American Journal of Physiology-Legacy Content. — 1928. — Vol.
86, iss. 3. — P. 599-613. DOI: 10.1152/ajplegacy.1928.86.3.599.
117. IW-3718 Reduces Heartburn Severity in Patients With Refractory
Gastroesophageal Reflux Disease in a Randomized Trial / M.F. Vaezi, R. Fass, N. Vakil,
[et al.] // Gastroenterology. – 2020. – Vol. 158. – № 8. – P. 2093–2103. DOI:
10.1053/J.GASTRO.2020.02.031.
118. Kashyap, D. Intrinsic and extrinsic pathways of apoptosis: Role in cancer
development and prognosis / D. Kashyap, V.K. Garg, N. Goel // Advances in Protein
Chemistry and Structural Biology. – 2021. – Vol. 125. – P. 73-120. doi:
10.1016/bs.apcsb.2021.01.003.
119. Ki-67 gene expression / S. Uxa, P. Castillo-Binder, R. Kohler, [et al.] // Cell Death
& Differentiation. – 2021. – Vol. 28. – № 12. – P. 3357-3370. DOI: 10.1038/s41418-02100823-x.
120. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Multivariate analysis of the
association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of
oesophagitis, the severity of oesophagitis and Barrett's oesophagus. Gut. 2008
Aug;57(8):1056-64. doi: 10.1136/gut.2006.119206.
121. Lagergren, J. Cholecystectomy as a risk factor for oesophageal adenocarcinoma /
J. Lagergren, F. Mattsson // British Journal of Surgery. – 2011. – Vol. 98. – № 8. – P.
1133-1137. DOI: 10.1002/bjs.7504.
122. Management of refractory typical GERD symptoms / E. Scarpellini, D. Ang, A.
Pauwels, [et al.] // Nature Reviews Gastroenterology & Hepatology. – 2016. – Vol. 13. –
P. 281–294.
123. Manifold, D.K. Effect of cholecystectomy on gastroesophageal and duodenogastric
reflux / D.K. Manifold, A. Anggiansah, W.J. Owen // Am J Gastroenterol. – 2000. – Vol.
95. – № 10. – P. 2746-2750. DOI: 10.1111/j.1572-0241.2000.02298.x.
124. Mean nocturnal baseline impedance: Influencing factors and diagnostic value in
gastroesophageal reflux disease / N. Wang, Z.H. Guo, Y.H. Wu, [et al.] // Technology
and Health Care. – 2023. – Vol. 31(5). – P. 1875-1886. DOI: 10.3233/THC-220814.
156
https://t.me/med1917
125. Mechanisms underlying duodeno-gastric reflux in man / G.H. Koek, R. Vos, D.
Sifrim, [et al.] // Neurogastroenterology & Motility. – 2005. – Vol. 17(2). – P. 191-9.
DOI: 10.1111/j.1365-2982.2004.00633.x.
126. Meining, A. Gastric inlet patches in the cervical esophagus: what they are, what
they cause, and how they can be treated / A. Meining, M. Bajbouj // Gastrointestinal
Endoscopy. — 2016. — Vol. 84, iss. 6. — P. 1027-1029. DOI:
10.1016/j.gie.2016.08.012.
127. Menges, M. Increased acid and bile reflux in Barrett’s esophagus compared to
reflux esophagitis, and effect of proton pump inhibitor therapy / M. Menges, M. Müller,
M. Zeitz // American Journal of Gastroenterology. – 2001. – Vol. 96. – № 2. – P. 331–
337. DOI: 10.1111/j.1572-0241.2001.03515.x.
128. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett’s
oesophagus / K. Altaf, J.J. Xiong, D. la Iglesia, [et al.] // British Journal of Surgery. –
2017. – Vol. 104. – № 5. – P. 493-502. DOI: 10.1002/bjs.10484.
129. Molinaro, A. Bile acid metabolism and FXR-mediated effects in human cholestatic
liver disorders / A. Molinaro, H. U. Marschall // Biochemical Society Transactions. –
2022. – Vol. 50. – P. 361-73.
130. Montgomery, E.A. Evaluation and reporting of biopsies from the columnar-lined
esophagus and gastro-esophageal junction (GEJ) / E.A. Montgomery, M.I. Canto, A.
Srivastava // Annals of Diagnostic Pathology. – 2019. – Vol. 39. – P. 111-117. DOI:
10.1016/j.anndiagpath.2019.02.012.
131. Naini, B.V. Barrett’s Esophagus: A Comprehensive and Contemporary Review for
Pathologists / B.V. Naini // American Journal of Surgical Pathology. – 2016. – Vol. 40(5).
– P. e45–e66.
132. Neutrophils, eosinophils, and intraepithelial lymphocytes in the squamous
esophagus in subjects with and without gastroesophageal reflux symptoms / M. Zand
Irani, N.J. Talley, J. Ronkainen, [et al.] // Human Pathology. – 2021. – Vol. 115. – P. 112-
122.
157
https://t.me/med1917
133. Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec
study / G.H. Koek, R. Vos, P. Flamen, [et al.] // Gut. – 2004. – Vol. 53. – № 1. – P. 21–
26. DOI: 10.1136/gut.53.1.21.
134. P53 and Ki-67 overexpression in gastroesophageal reflux disease–Barrett’s
esophagus and adenocarcinoma sequence / M. Binato, R.R. Gurski, R.B. Fagundes, [et
al.] // Diseases of the Esophagus. – 2009. – Vol. 22. – № 7. – P. 588-95. DOI:
10.1111/j.1442-2050.2009.00953.x.
135. Pathogenesis of Barrett’s esophagus: bile acids inhibit the Notch signaling pathway
with induction of CDX2 gene expression in human esophageal cells / D.J. Morrow, N.E.
Avissar, L. Toia, [et al.] // Surgery. – 2009. – Vol. 146. – № 4. – P. 714-21. DOI:
10.1016/j.surg.2009.06.050
136. Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update
of the State-of-the-Art / V. Savarino, E. Marabotto, P. Zentilin, [et al.] // Drug Design,
Development and Therapy. – 2021. – Vol. 15. – P. 1609–1621. DOI:
10.2147/DDDT.S306371.
137. Pittman, M.E. Lymphocyte-predominant Esophagitis: A Distinct and Likely
Immune-mediated Disorder Encompassing Lymphocytic and Lichenoid Esophagitis /
M.E. Pittman, E. Hissong, P.O. Katz, [et al.] // American Journal of Surgical Pathology.
– 2020. – Vol. 44. – № 2. – P. 198-205. DOI: 10.1097/PAS.0000000000001394
138. Pohl, D. Reflux monitoring: pH-metry, Bilitec and oesophageal impedance
measurements / D. Pohl, R. Tutuian // Best Practice & Research Clinical
Gastroenterology. – 2009. – Vol. 23. – № 3. – P. 299–311. DOI:
10.1016/J.BPG.2009.04.003.
139. Postreflux swallow-induced peristaltic wave index and nocturnal baseline
impedance can link PPI-responsive heartburn to reflux better than acid exposure time / L.
Frazzoni, M. Frazzoni, N. de Bortoli, [et al.] // Neurogastroenterology & Motility. – 2017.
– Vol. 29(11). DOI: 10.1111/nmo.13116.
140. Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive
to proton pump inhibitors / L. Monaco, A. Brillantino, F. Torelli, [et al.] // World Journal
of Gastroenterology. – 2009. – Vol. 15. – № 3. – P. 334-338.
158
https://t.me/med1917
141. Prevalence of pathological duodenogastric reflux and the relationship between
duodenogastric and duodenogastrooesophageal reflux in chronic gastrooesophageal
reflux disease / A. Brillantino, L. Monaco, M. Schettino, [et al.] // European Journal of
Gastroenterology & Hepatology. – 2008. – Vol. 20(12). – P. 1136-43. DOI:
10.1097/MEG.0b013e32830aba6d
142. Production of a mouse monoclonal antibody reactive with a human nuclear antigen
associated with cell proliferation / J. Gerdes, U. Schwab, H. Lemke, [et al.] // International
Journal of Cancer. – 1983. – Vol. 31. – № 1. – P. 13-20. DOI: 10.1002/ijc.2910310104.
143. Production of prostaglandin E2 via bile acid is enhanced by trypsin and acid in
normal human esophageal epithelial cells / A. Kawabe, Y. Shimada, T. Soma, [et al.] //
Life Sciences. – 2004. – Vol. 75. – № 1. – P. 21-34. – DOI: 10.1016/j.lfs.2003.11.022
144. Prognostic value of stem cell markers in esophageal and esophagogastric junction
cancer: a meta-analysis / E. Trevellin, G. Pirozzolo, M. Fassan, [et al.] // Journal of
Cancer. – 2020. – Vol. 11. – № 14. – P. 4240–4249. DOI: 10.7150/JCA.33699.
145. Prospective evaluation of duodenogastroesophageal reflux in gastroesophageal
reflux disease patients refractory to proton pump inhibitor therapy / S. Kunsch, A. Neesse,
T. Linhart, [et al.] // Digestion. – 2012. – Vol. 86. – № 4. – P. 315–322. doi:
10.1159/000342234.
146. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2
transfection on morphology and gene expression of human esophageal epithelial cells /
T. Liu, X. Zhang, C.K. So, [et al.] // Carcinogenesis. – 2007. – Vol. 28. – № 2. – P. 488-
96. DOI: 10.1093/carcin/bgl176
147. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2
transfection on morphology and gene expression of human esophageal epithelial cells /
T. Liu, X. Zhang, C.K. So, [et al.] // Carcinogenesis. – 2007. – Vol. 28. – № 2. – P. 488-
96. DOI: 10.1093/carcin/bgl176.
148. Rehfeld, J. F. Cholecystokinin and the hormone concept / J. F. Rehfeld // Endocrine
Connections. — 2021. — Vol. 10, iss. 3. — P. 139-150. DOI: 10.1530/ec-21-0025.
159
https://t.me/med1917
149. Richter, J. E. Duodenogastric reflux-induced (alkaline) esophagitis / J. E. Richter
// Current Treatment Options in Gastroenterology. – 2004. – Vol. 7, No. 1. – P. 53-58. –
DOI 10.1007/s11938-004-0025-1
150. Role of a novel bile acid receptor TGR5 in the development of oesophageal
adenocarcinoma / J. Hong, J. Behar, J. Wands, [et al.] // Gut. – 2010. – Vol. 59. – № 2. –
P. 170-80. DOI: 10.1136/gut.2009.188375.
151. Role of acid and bile reflux in development of specialised intestinal metaplasia in
distal oesophagus / G. Zaninotto, G. Portale, A. Parenti, [et al.] // Digestive and Liver
Disease. – 2002. – Vol. 34. – № 4. – P. 251-257. DOI: 10.1016/s1590-8658(02)80144-x.
152. Sararu E.R. Association between Mean Nocturnal Baseline Impedance (MNBI)
and Post-Reflux Swallow-Induced Peristaltic Wave Index (PSPW) in GERD Patients /
E.R. Sararu, R. Peagu, C. Fierbinteanu-Braticevici // Diagnostics (Basel). – 2023. – Vol.
13(24). – P. 3602. DOI: 10.3390/diagnostics13243602.
153. Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly
acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces /
R. Farré, H. van Malenstein, R. De Vos, [et al.] // Gut. – 2008. – Vol. 57(10). – P. 1366-
74. DOI: 10.1136/gut.2007.141804.
154. Souza, R.F. The Role of Acid and Bile Reflux in Esophagitis and Barrett’s
Metaplasia / R.F. Souza // Biochemical Society Transactions. – 2010. – Vol. 38(2). – P.
348–352.
155. SOX2 interferes with the function of CDX2 in bile acid-induced gastric intestinal
metaplasia / T. Yuan, Z. Ni, C. Han, [et al.] // Cancer Cell International. – 2019. – Vol.
19. – P. 24. DOI: 10.1186/s12935-019-0739-8.
156. Squier, C.A. Biology of oral mucosa and esophagus/ C.A. Squier, M.J. Kremer //
Journal of the National Cancer Institute Monographs. – 2001. – Vol. 29. – P. 7-15. DOI:
10.1093/oxfordjournals.jncimonographs.a003443.
157. Steiner, S.J. Severity of basal cell hyperplasia differs in reflux versus eosinophilic
esophagitis / S.J. Steiner, K.M. Kernek, J.F. Fitzgerald // Journal of Pediatric
Gastroenterology and Nutrition. – 2006. – Vol. 42(5). – P. 506-9. DOI:
10.1097/01.mpg.0000221906.06899.1b.
160
https://t.me/med1917
158. Stratification and symptom characteristics of non-erosive reflux disease based on
acid and duodenogastroesophageal reflux / L.S. Xiong, M.H. Chen, J.K. Lin, [et al.] //
Journal of Gastroenterology and Hepatology. – 2008. – Vol. 23. – № 2. – P. 290-295.
DOI: 10.1111/j.1440-1746.2007.05152.x.
159. Sun, X. Ki-67: more than a proliferation marker / X. Sun, P.D. Kaufman //
Chromosoma. – 2018. – Vol. 127. – № 2. – P. 175-186. DOI: 10.1007/s00412-018-0659-
8.
160. Sun, Y.M. Role of Esophageal Mean Nocturnal Baseline Impedance and Postreflux Swallow-induced Peristaltic Wave Index in Discriminating Chinese Patients With
Heartburn / Y.M. Sun, Y. Gao, F. Gao // Journal of Neurogastroenterology and Motility.
– 2019. – Vol. 25(4). – P. 515-520. DOI: 10.5056/jnm19056.
161. Surface Ki-67 Expression Improves Reproducibility of Dysplasia Diagnosis in
Barrett’s Esophagus / H. Yousaf, U. Hayat, J. Manivel, [et al.] // American Journal of
Clinical Pathology. – 2020. – Vol. 153. – № 5. – P. 695-704. DOI:
10.1093/AJCP/AQAA004.
162. Svensson, J. O. Gallstones, Cholecystectomy, and Duodenogastric Reflux of Bile
Acid / J. O. Svensson, J. Gelin, J. Svanvik // Scandinavian Journal of Gastroenterology.
— 1986. — Vol. 21, iss. 2. — P. 181-187. DOI: 10.3109/00365528609034644.
163. Symptoms of oesophageal reflux are more common following laparoscopic
cholecystectomy than in a control population / D.A. McNamara, M.K. O’Donohoe, P.G.
Horgan, [et al.] // Ir J Med Sci. – 1998. – Vol. 167. – № 1. – P. 11-13. DOI:
10.1007/BF02937544.
164. Systematic review: duodenogastroesophageal (biliary) reflux prevalence,
symptoms, oesophageal lesions and treatment / C. Basnayake, A. Geeraerts, A. Pauwels,
[et al.] // Alimentary Pharmacology & Therapeutics – 2021. – Vol. 54. – № 6. – P. 755-
778. DOI: 10.1111/apt.16533
165. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal
reflux disease and related neoplasia / McQuaid K.R., Laine L., Fennerty M.B., [et al.] //
Aliment Pharmacol Ther. – 2011. – Vol. 34, No. 2. – P. 146–165. doi: 10.1111/j.1365-
2036.2011.04709.x.
Соседние файлы в папке @xirurgi_2025